No Data
No Data
Haichuang Pharmaceutical (688302.SH) announced first-quarter results with a net loss of 47.21 million yuan
According to the Zhitong Finance App, Haichuang Pharmaceutical (688302.SH) disclosed its report for the first quarter of 2024. During the reporting period, the company achieved a revenue of 0 yuan; a net profit loss of 47.21 million yuan; and a loss of 52.72 million yuan after deducting non-net profit. Basic earnings per share - $0.48.
Express News | Haichuang Pharmaceutical: First quarter revenue of 0 yuan
Southwest Securities released a research report on April 15 stating that it gave Haichuang Pharmaceutical (688302.SH) a purchase rating. The main reasons for the evaluation include: 1) NDA for deuterium enzalutamide softgels was accepted by the NMPA and i
Southwest Securities released a research report on April 15 stating that it gave Haichuang Pharmaceutical (688302.SH) a purchase rating. The main reasons for the evaluation include: 1) NDA for deuterium enzalutamide softgels was accepted by the NMPA and is expected to become the first AR inhibitor approved for mCRPC second-line treatment in China; 2) HP518 completed its first case of administration to subjects at the end of 23 years of phase I/II clinical trials, and is the first oral ARPROTAC drug to enter the clinical stage in China; 3) multiple clinical trials have been approved, and progress is being accelerated in the research pipeline. (Mainichi Keizai Shimbun)
Haichuang Pharmaceutical (688302.SH) reported 2023 annual results, unrealized revenue, net loss of 294 million yuan
Haichuang Pharmaceutical (688302.SH) released its 2023 annual report. The company did not achieve operating income during the reporting period; net loss attributable to shareholders of listed companies was 294 million yuan, narrowing the year-on-year loss; net loss attributable to shareholders of listed companies was deducted by 325 million yuan in non-recurring profit and loss, which narrowed year-on-year loss; basic loss per share was 2.97 yuan/share.
Haichuang Pharmaceutical (688302): Deuterium enzalutamide is expected to be approved for marketing by the end of 2024
Incident: The company released its 2023 annual report. As of December 31, 2023, the company has not made a profit and has accumulated uncompensated losses. Net profit attributable to mother in 2023 - 294 million yuan, net profit not attributable to mother - 3.25 million yuan
Hinova Pharma Gets Nod to Trial HP501 Tablets; Shares Down 3%
Hinova Pharmaceuticals (SHA:688302) will conduct clinical trials on HP501 extended-release tablets after receiving approval from China's National Medical Products Administration, the company said in i
No Data